After 256 cases of fatal bleeding, the European Medicines Agency urged doctors to exercise caution when using Boehringer Ingelheim's stroke-prevention drug Pradaxa. The agency said the pill demonstrates unchanged efficacy but needs to be administered in lower doses in patients older than 75 to adequately manage bleeding risk.

Full Story:

Related Summaries